Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. - Wikidata - awgldk - TriplyDB

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.

http://www.wikidata.org/entity/Q36643142

about

Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Circulating biomarkers to monitor cancer progression and treatment Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma.Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients Recent advances in the biology of human circulating tumour cells and metastasis Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer Antibody-independent capture of circulating tumor cells of non-epithelial origin with the ApoStream® system.Liquid biopsy genotyping in lung cancer: ready for clinical utility?Circulating Tumor Cells Identify Early Recurrence in Patients with Non-Small Cell Lung Cancer Undergoing Radical Resection Re-biopsy by endobronchial ultrasound procedures for mutation analysis of non-small cell lung cancer after EGFR tyrosine kinase inhibitor treatment.Diagnostic Utility of Pleural Fluid Cell Block versus Pleural Biopsy Collected by Flex-Rigid Pleuroscopy for Malignant Pleural Disease: A Single Center Retrospective Analysis.Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors.Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study.Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment.Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the disease Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkers Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?: A meta-analysis.Molecular profiling of single circulating tumor cells from lung cancer patients.Liquid Biopsies for Cancer: Coming to a Patient near You.Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations.Plasma T790M and HGF as potential predictive markers for EGFR-TKI re-challenge.Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective.Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer.Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer.The prognostic role of circulating tumor cells in lung cancer.Pathologists and liquid biopsies: to be or not to be?Osimertinib for the treatment of non-small cell lung cancer.The promise of circulating tumor cells for precision cancer therapy.Liquid Biopsy in Non-Small Cell Lung Cancer.Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.Transient appearance of circulating tumor DNA associated with de novo treatment.

P2860

Q26741814-BCF746C8-14FF-44F9-8C7A-201B33B82347 Q26745985-1BED221C-F784-4115-B890-E8F3FEFC3D4C Q27853391-F17E9F5F-3E56-48B1-BE2A-4BFCBB4E829C Q28066285-00375FC5-0988-4518-876E-2A4345435533 Q28067439-68BF77B5-4A00-44EC-829F-601504C6FEF2 Q28070120-B79C5317-3B06-464A-A583-EB097BD6667E Q28073765-21BEB1F1-9DAF-4286-99B1-725291193E81 Q28075800-00D03252-2287-4908-B6E3-4C2ABBF861F6 Q28076191-30F8EE3B-CD5B-4F99-B5EB-C8F66D25A34C Q28079253-B6E6DD4F-B689-4D71-8347-0A096F83E379 Q33558772-9DC3A7EC-4501-404F-82E5-5E3DBC5434A2 Q33567037-8AB4EE60-4EB8-4932-A59C-0FF172FBEB42 Q35935317-02BD7CA4-2FFF-4FA7-BEA6-F6933C82F5D8 Q36085487-81DF4BB6-B12D-499A-A6CF-D6B49BC472BC Q36202696-8151C180-9547-49E5-A12A-FDF27847A850 Q36270828-569F3905-46DE-45DF-A949-79C7B8BA97EE Q36622073-B62A7CDC-F0AD-4148-93CD-62CE30CD77E6 Q36746250-2E763D91-7C65-47CF-B06F-F7DEE35F35B1 Q36834331-08386BEF-4C62-43B7-92E0-E39EB19442AC Q37295773-5FC92EA9-3CA1-4572-AAF4-4FDB937369EC Q37468081-371CC414-F137-4BEC-B2D8-67D0AE1EE2A9 Q37549994-BE3A3503-993C-429B-A418-1D761DA8F17A Q37628173-8178C1B2-92F1-44B1-AA2A-DA6B2883EA85 Q37687088-5F274C6B-B887-4E08-8C58-A5FBEDF3DDC9 Q37690677-D5DDAF33-0840-4C36-89DD-D9A249FFE5C8 Q37709148-58C9F401-BB3C-4B42-82F8-6FDA140E6FF4 Q38598893-13A3A66E-7B63-482B-9FBB-975DABD127C8 Q38651333-EB4351F0-209D-475D-93FE-D8D991F5E42C Q38673986-9CF6CE56-99AB-44CD-9DA9-2C7B9476ECBC Q38685481-92239397-725C-48C8-B123-2D7B5A03246B Q38717500-CAFA3790-7242-4D31-9B4D-99B06C765337 Q38772190-66007C13-5F89-41FC-B98F-0B09CF236B1F Q38824891-BB4B02CF-EFD4-4C9D-BF76-ACBD4B6007FB Q38874709-C60BC62B-53B1-4F8B-BD72-28FDEE0FCC81 Q38935060-39D0A6D3-8E47-4124-963E-80A266F00439 Q39002726-837DB2F7-F029-49BB-AA43-1A31F64F7879 Q39031157-3B850533-AEFA-452A-8287-FC4349DC0378 Q39076207-B4671F2A-17F7-4A8F-A1BF-072091B8415D Q39106800-61F20773-769C-450C-9E49-1BE22C55EEF1 Q39116247-BB7BEBCA-6656-4D0D-BAFD-EEB7179F07BD

P2860

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.

http://www.wikidata.org/entity/Q36643142

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Detection of T790M, the Acquir ...... invasive Blood-Based Analyses.

@ast

Detection of T790M, the Acquir ...... invasive Blood-Based Analyses.

@en

type

label

Detection of T790M, the Acquir ...... invasive Blood-Based Analyses.

@ast

Detection of T790M, the Acquir ...... invasive Blood-Based Analyses.

@en

prefLabel

Detection of T790M, the Acquir ...... invasive Blood-Based Analyses.

@ast

Detection of T790M, the Acquir ...... invasive Blood-Based Analyses.

@en

P1433

Q36643142-90BD5B8B-6BDA-42CE-AD41-3697533E9ED1

P1476

Q36643142-68B21C8A-0AE5-4760-B403-D8545EA9C1C2

P2093

Q36643142-24CB9FBB-0E0F-43E2-A896-185115940E2E

Q36643142-27D9CF35-2010-4458-AFAC-F2E146D02448

Q36643142-28C4E50A-77D6-4212-A72F-B552E5086DC0

Q36643142-2CC56A63-F3D6-4859-94AC-A7F5D79B96D3

Q36643142-6B3491DE-0193-47BE-B637-DFF26AE67D66

Q36643142-762FB3D0-9B8D-42B8-972E-EC618082BB15

Q36643142-7E96927C-3465-43DD-A0F5-A7E1B2776C2D

Q36643142-9C753113-0E25-4AA3-BCF7-2539B25137F0

Q36643142-A8AC6A4F-C763-45E2-9E79-327A7630AC5B

Q36643142-B5A1900D-F576-4FC6-B67F-1BD8312753FA

P2860

Q36643142-0E27DBCE-0A44-4292-9D94-557AB7A3537D

Q36643142-1E950B84-E23A-4ACC-A39C-6448FF4F62BE

Q36643142-21D7D81D-2831-468B-AA9E-369D88069321

Q36643142-24D01ED1-B4D9-4864-9DEF-6549E6558F98

Q36643142-3C064ADB-5048-4403-A863-30469D565B5F

Q36643142-4E4188B1-A4CD-430D-80A7-E175E3ACFBA4

Q36643142-681846AF-8AD1-4E94-A518-CF373208A5FE

Q36643142-6A9171A5-D900-46AB-B095-1971595B8328

Q36643142-6CD06EA8-D643-4C48-A434-771A23EFF726

Q36643142-73460E79-1646-4736-ADD6-880D0D2D63FE

P304

Q36643142-2A09086D-BD5D-4FAC-98D1-AC43D3A97DAE

P31

Q36643142-99F4128E-A2AF-48BF-9BF5-6F32482A6A28

P356

Q36643142-DECC50BF-69F1-4C5B-B202-AE2E708D6518

P407

Q36643142-4197FE89-84AC-4883-8337-6BA5F961CBA8

P433

Q36643142-B7483A45-9F4A-4DCE-9416-28FF4F58026A

P478

Q36643142-7D6D51D2-E4C1-4618-A129-6CCF5552F62C

P50

Q36643142-3014395A-6B34-40E3-9E6E-0D624E4CEE15

Q36643142-6FC5E18D-C8B1-494F-B231-CCC5F37D4FCB

Q36643142-F361EF43-D5D0-401C-B7E9-C83B5CBFF96A

P577

Q36643142-C18659B7-7B77-4FCE-A2BE-D632826FC5C5

P698

Q36643142-EF4E6BFC-EA0B-4394-8DB2-B5F56FC1AF7F

P932

Q36643142-E7D96147-8D6B-4F20-A7F8-C0BF73A18B8E

P356

1078-0432.CCR-15-1031

P1433

Clinical Cancer Research

P1476

Detection of T790M, the Acquir ...... invasive Blood-Based Analyses.

@en

P2093

Alona Muzikansky

http://www.w3.org/2001/XMLSchema#string

Andrew Webb

http://www.w3.org/2001/XMLSchema#string

Bruce E Johnson

http://www.w3.org/2001/XMLSchema#string

Daniel A Haber

http://www.w3.org/2001/XMLSchema#string

Douglas B Fox

http://www.w3.org/2001/XMLSchema#string

Gregory J Riely

http://www.w3.org/2001/XMLSchema#string

Hai T Tran

http://www.w3.org/2001/XMLSchema#string

Helena A Yu

http://www.w3.org/2001/XMLSchema#string

James P Sullivan

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Engelman

http://www.w3.org/2001/XMLSchema#string

P2860

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

P304

1103-1110

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-15-1031

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26446944

http://www.w3.org/2001/XMLSchema#string

P932

4775471

http://www.w3.org/2001/XMLSchema#string